Samsung Biologics to acquire PolyPeptide for KRW 2.7 trillion, creating South Korea’s largest pharma M&A deal
Samsung Biologics said on July 20 that it has signed an agreement to acquire PolyPeptide Group, a global peptide drug CDMO, for about 2.7 trillion won (about $1.46 billion in Swiss francs)—the largest M&A deal in history for Korea’s pharmaceutical and biotech industry. After the announcement, the stock closed the same day at 1,359,000 won, down 37,000 won. July 20 M&A Agreement: Acquisition Price, Equity Structure, and December-End Completion Timeline According to Samsung Biologics’ public discl
Samsung Biologics10.07%
NVO1.22%
MarketWhisper·07-20 02:11







